|
Name of the Drug
|
Name of te impurity
|
CAS
|
Molecular Formula
|
Molecular Wt
|
|
Vortioxetine HBr
|
Vortioxetine
|
508233-74-7
|
C18H22N2S
|
298.45
|
|
1-(2-(o-tolylthio)phenyl)piperazine
|
1293489-71-0
|
C17H20N2S
|
284.43
|
|
|
1-(2-(m-tolylthio)phenyl)piperazine
|
1293489-69-6
|
C17H20N2S
|
284.43
|
|
|
1-(2-(p-tolylthio)phenyl)piperazine
|
508233-82-7
|
C17H20N2S
|
284.43
|
|
|
1-(2-((2,3-dimethylphenyl)thio)phenyl)piperazine
|
1293343-33-5
|
C18H22N2S
|
298.45
|
|
|
1-(2-(2,6-dimethylphenylthio)phenyl)piperazine
|
C18H22N2S
|
299.45
|
||
|
1-(2-(3,4-dimethylphenylthio)phenyl)piperazine
|
C18H22N2S
|
300.45
|
||
|
1,2-bis(2,4-dimethylphenyl)disulfane
|
13616-83-6
|
C16H18S2
|
274.44
|
|
|
2,4‐dimethyl‐1‐(phenylsulfanyl)benzene
|
16704-47-5
|
C14H14S
|
214.33
|
|
|
1-[2-[(2,4-Dimethylphenyl)sulfinyl]phenyl]piperazine (Vortioxetine Sulfoxide)
|
1429908-35-9
|
C18H22N2OS
|
314.45
|
|
|
Pazopanib
|
5-amino-2-methyl benzene sulphonamide
|
6973–09-7
|
C7H10N2O2S
|
186.23
|
|
N-(2-Chloropyrimidin-4-yl)N-2,3-trimethyl-2H-indazol-6-amine
|
444731-75-3
|
C14H14ClN5
|
288
|
|
|
1,3-Dimethylindazol-6-amine
|
221681-92-1
|
C10H13N2
|
161.21
|
|
|
2,3-Dimethyl-6-amino-2H-indazole Hydrochloride
|
635702-60-2
|
C9H12ClN3
|
197.67
|
|
|
2,3-Dimethyl-6-nitro-2H-indazole
|
444731-73-1
|
C9H9N3O2
|
191.19
|
|
|
6-Chloropyrimidin-2(1H)-one
|
80927-55-5
|
C4H3ClN2O
|
130.53
|
|
|
Pazopanib Related Compound 2
|
1226500-02-2
|
C26H23ClN10
|
510.99
|
|
|
Pazopanib Related Compound 3
|
1252927-44-8
|
C27H25ClN10
|
525.02
|
|
|
Pazopanib Related Compound 4
|
6274-28-8
|
C7H10N2O2S
|
186.23
|
|
|
Prazosin HCl
|
Prazosin Impurity A (4-Amino-2-chloro-6,7-dimethoxyquinazoline)
|
23680-84-4
|
C10H10ClN3O2
|
239.66
|
|
Prazosin Impurity B (1,4-Bis(furan-2-ylcarbonyl)piperazine)
|
31350-27-3
|
C14H14N2O4
|
274.27
|
|
|
Prazosin Impurity C (2-Piperazine-4-amino-6,7-dimethoxyquinazoline)
|
60547-97-9
|
C14H19N5O2
|
289.3
|
|
|
Prazosin Impurity D- 1-(2-Furoyl)piperazine
|
40172-95-0
|
C9H12N2O2
|
180.2
|
|
|
PRAZOSIN – IMPURITY E – 2,2′-(PIPERAZIN-1,4-DIYL)BIS- (6,7-DIMETHOXYQUINAZOLIN-4-AMINE)
|
102839-00-9
|
C24H28N8O4
|
492.53
|
|
|
2-Chloro-6,7-dimethoxyquinazolin-4-yl Chloride
|
27631-29-4
|
C10H8Cl2N2O2
|
259.1
|
|
|
6,7-Dimethoxy-2,4(1H,3H)-quinazolinedione
|
28888-44-0
|
C10H10N2O4
|
222.2
|
|
|
Prazosin HCl
|
19237-84-4,
|
C19H21N5O4·HCl
|
383.4
|
|
|
Doxazosin
|
Doxazosin – impurity A (1,4-Benzodioxan-2-carboxylic acid)
|
3663-80-7, 34385-93-8
|
C9H8O4
|
180.16
|
|
Doxazosin – impurity B N-(1,4-Benzodioxane-2-carbonyl)piperazine hydrochloride
|
70918-74-0
|
C13H16N2O3
|
248.28
|
|
|
Doxazosin – impurity C N,N-bis(1,4-Benzodioxane-2-carbonyl)piperazine
|
617677-53-9
|
C22H22N2O6
|
410.43
|
|
|
Doxazosin – impurity D 6,7-Dimethoxy-2,4(1H,3H)-quinazolinedione
|
28888-44-0
|
C10H10N2O4
|
222.2
|
|
|
Doxazosin – impurity E 2-Chloro-6,7-dimethoxyquinazolin-4-yl Chloride
|
27631-29-4
|
C10H8Cl2N2O2
|
259.1
|
|
|
Doxazosin – impurity F (4-Amino-2-chloro-6,7-dimethoxyquinazoline)
|
23680-84-4
|
C10H10ClN3O2
|
239.66
|
|
|
Doxazosin Impurity G (2-Piperazine-4-amino-6,7-dimethoxyquinazoline)
|
60547-97-9
|
C14H19N5O2
|
289.3
|
|
|
Doxazosin Impurity -H 2,2′-(Piperazin-1,4-diyl)bis- (6,7-dimethoxyquinazolin-4-amine)
|
102839-00-9
|
C24H28N8O4
|
492.53
|
|
|
Alfuzosin
|
Alfuzosin Tetradehydro Impurity (Alfuzosin EP Impurity A)
|
98902-36-4, 98902-29-5 (HCl Salt)
|
C19H23N5O4
|
385.42
|
|
Alfuzosin EP Impurity B
|
23680-84-4
|
C10H10ClN3O2
|
239.66
|
|
|
Alfuzosin EP Impurity C -N-[3-[(4-Amino-6,7-dimethoxyquinazolin-2-yl)amino]propyl]-N-methyltetrahydrofuran-2-carboxamide hydrochloride
|
98902-34-2
|
C19H27N5O4
|
389.46
|
|
|
Alfuzosin EP Impurity D, Alfuzosin Aminopropyl
|
81403-69-2 (HCl Salt),76362-29-3
|
C14H21N5O2
|
291.36
|
|
|
Alfuzosin EP Impurity E, N-[3-[(4-Amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl]formamide hydrochloride
|
1026411-59-5
|
C15H21N5O3. HCl
|
319.37
|
|
|
6,7-dimethoxy-N2,N2-dimethylquinazoline-2,4-diamine
|
19216-53-6
|
C12H16N4O2
|
248.29
|
“If you have similar requirements, please feel free to contact us for more information, we’d be very pleased to discuss more details regarding how we can serve your specific needs.”